Comparative advantage of anti-Mullerian hormone over other ovarian reserve metric (basal hormonal test) in prediction of fertility in women with varying menstrual cycle

Main Article Content

Fidelis Ohiremen Oyakhire
Cedric Odaro
Enehizena Osaro Ogie
Eseoghene Valentine Egho
Joy Akpesiri Egho
Ekomobong Effiong Idem
Irabonosa Asiriuwa
Adebukola Adisa Ekoh-Jolly
Nnamdi Bede Aneke


Objective: Anti-Mullerian hormone has been indicated as a novel biomarker for ovarian reserve assessment. This study aimed to determine the comparative advantage of serum levels of AMH, FSH, LH, E2, and  LH/FSH ratio among women with varying menstrual cycles and duration of menstruation.  

Material and Method: A total of 90 subjects, which consisted of sixty subjects and thirty healthy subjects as control, were recruited. Blood samples were collected on day 3 of the menstrual cycle and evaluated for ovarian markers using the ELISA technique. All data were analyzed using SPSS version 23.0.

Results: AMH and LH/FSH levels were lower in women with varying menstrual cycles than in the control group. FSH, LH, and E2 levels were significantly higher in women with varying menstrual cycles and flow duration than in the control group(P<0.05).  AMH was negatively correlated with age (r= -0.72), BMI( r= -0.4), FSH(r= - 0.3), LH(r = -0.2) (p<0.05) and E2(r= -0.2, p>0.05). Also age was positively correlated with FSH(r=0.5,p<0.05), E2(r=0.3, p<0.05) and BMI(r=0.4, p<0.05). The level of AMH was not significant with cycle length and days of flow(p>0.05). This implies that AMH can be measured independently of the cycle phase. This show that AMH was lower in women with varying menstrual cycle with an increase in gonadotrophin and E2. The strong negative relationship between age and AMH implies that age is determining factor of ovarian reserve. 

Conclusion: AMH combined with age and FSH may improve ovarian reserve evaluation, making AMH a better marker


Download data is not yet available.

Article Details

How to Cite
Oyakhire, F. O., Odaro, C., Osaro Ogie, E. ., Valentine Egho, E. ., Akpesiri Egho, J. ., Effiong Idem, E. ., Asiriuwa, I. . ., Adisa Ekoh-Jolly, A. ., & Bede Aneke, N. . (2022). Comparative advantage of anti-Mullerian hormone over other ovarian reserve metric (basal hormonal test) in prediction of fertility in women with varying menstrual cycle. Medical Science and Discovery, 9(1), 12–21.
Research Article
Received 2021-12-28
Accepted 2022-01-09
Published 2022-01-11


Bradley SEK, Chelsea BP, Akinrinola B, Trevor C.: Global Contraceptive Failure Rates: Who Is Most at Risk? Studies in Family Planning, 2019; 50, 3-24. DOI:

Hiadzi RA, Bryan, JW.: Infertility Treatment Decision-Making in Ghana and Contestations That May Arise: A Prospective Sociological Study. Global Reproductive Health, 2019 4, e32. DOI:

Leridon H.: Can Assisted Reproduction Technology Compensate for the Natural Decline in Fertility with Age? A Model Assessment. Human Reproduction, 2004; 19, 1548-1553. DOI:

Moolhuijsen LME, Visser, JA. : Anti-Müllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function. The Journal of Clinical Endocrinology & Metabolism,2020; 105, 3361-3373. DOI:

Lehmann P, Maria PV, Julio S, Louise P, Wael J, François B, Simo P, Isaac-Jacques K. : Anti-Müllerian Hormone (AMH): A Reliable Biomarker of Oocyte Quality in IVF. Journal of Assisted Reproduction and Genetic, 2014; 31, 493-498. DOI:

Practice Committee of the American Society for Reproductive Medicine (ASRM): Testing and Interpreting Measures of Ovarian Reserve: A Committee Opinion. Fertility and Sterility, 2015; 103, e9-e17. DOI:

Ferraretti AP, Gianaroli L. (2014) The Bologna Criteria for the Definition of Poor Ovarian Responders: Is There a Need for Revision? Human Reproduction, 2014; 29, 1842-1845. DOI:

Gianaroli, L.: Best Practices of ASRM and ESHRE: A Journey through Reproductive Medicine. Fertility and Sterility,2012; 98, 1380-1394. DOI:

Seifer DB, Maclaughlin DT. Mullerian Inhibiting Substance Is an Ovarian Growth Factor of Emerging Clinical Significance. Fertility and Sterility,2007; 88, 539-546. DOI:

Silva MSB, Giacobini P.:New Insights into Anti-Müllerian Hormone Role in the Hypothalamic-Pituitary-Gonadal Axis and Neuroendocrine Development. Cellular and Molecular Life Sciences,2020. DOI:

Catherine D, McCormack- Shalem YL, Denise LF, Gustaaf AD, Claire TR.: Anti-Müllerian Hormone Levels in Recurrent Embryonic Miscarriage Patients Are Frequently Abnormal, and May Affect Pregnancy Outcomes. Journal of Obstetrics and Gynaecology,2019; 39, 623-627. DOI:

Broer SL.: Anti-Mullerian Hormone Predicts Menopause: A Long-Term Follow-Up Study in Normoovulatory Women. Journal of Clinical Endocrinology and Metabolism,2011; 96, 2532-2539. DOI:

Hansen KR.: Correlation of Ovarian Reserve Tests with Histologically Determined Primordial Follicle Number. Fertility and Sterility, 2011; 95, 170-175. DOI:

van Disseldorp (2010) Comparison of Inter- and Intra-Cycle Variability of Anti Mullerian Hormone and Antral Follicle Counts. Human Reproduction, 25, 221-227. DOI:

Scott RT Jr, Hofmann GE.: Prognostic assessment of ovarian reserve, Fertil. Steril, 1995; 63 : 1-11 DOI:

Sharara FI, McClamrock HD.: The effect of aging on ovarian volume measurement in infertile Women. Obstet. Gynecol, 1999; 94: 57-60 DOI:

Stephen EH, Chandra A.:Declining estimates of infertility in the United States. 1992-2002. Fertil.Steril.2006; 86 DOI:

United States Centers for Disease Control and Prevention. Assisted reproductive technology report. 2015 Available at: ART2005/section4.htm. Accessed April 23, 2018.

Coulam CB, Adamson SC, Anneger JF.: Incidence of premature ovarian failure, Obstet Gynecol, 1986; 67: 604-606

Coulam CB, Stringfellow S, Hoefnagel D.: Evidence of genetic factor in the etiology of premature ovarian failure, Fertil. Steril, 1982; 40: 693-695 DOI:

Broekmans, F.J., Visser, J.A., Laven, J.S.E., Broer, S.L., Themmen, A.P.N. and Fauser, B.C. (1998). Anti- Mullerian hormone and ovarian dysfunction. Trends Endocrinology and Metabolism, 1998; 9: 340-7. DOI:

Bukman A, Heinman MJ.: Ovarian reserve testing and use of the prognostic model in patients with Subfertility. Human Reprod Update , 2001; 7(6) 581-590 DOI:

Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. : A systematic review of tests predicting ovarian reserve and IVF outcome. Human Reproductive Update. 2006; 12: 685 – 718. DOI:

Sherman BM, West JH, Korenman SG.: The menopausal transition: analysis of LH, FSH, estradiol, and progesterone concentrations during menstrual cycles of older women. Journal of Clinical Endocrinology and Metabolism. 2006 42: 629 – 636. DOI:

Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson JF.: Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Human Reproduction .2012;7:1342–6. DOI:

Sabatini L, Zosmer A, Hennessy EM, Tozer A, Al-Shawaf T.: Relevance of basal serum FSH to IVF outcome varies with patient age. Reproductive Biomedical Online. 2008; 17: 10 – 19. DOI:

Lee TH, Liu CH, Huang CC, Hsieh KC, Lin PM, Lee MS.:Impact of female age and male infertility on ovarian reserve markers to predict the outcome of assisted reproduction technology cycles. Reproductive Biology and Endocrinology. 2009; 7: 100. DOI:

Broekmans, FJ, de ZD, Howles CM, Gougeon A, Trew G, Olivennes F.: The antral follicle count: practical recommendations for better standardization. Fertility and Sterility.2010; 94: 1044 – 1051. DOI:

Broekmans FJ, Faddy MJ, Scheffer G, te Velde ER.: Antral follicle counts are related to age at natural fertility loss and age at menopause. Menopause. 2004;11(61): 607 – 614. DOI:

te Velde ER, Pearson PL.: The variability of female reproductive aging. Hum Reprod Update 2002;8:141–254. DOI:

Broekmans FJ, Soules MR, Fauser BC.: Ovarian aging: mechanisms and clinical consequences. Endocrinology and Review. 2009;30: 465 – 493. DOI:

Hehenkamp WJ, Looman CW, Themmen AP, de Jong FH, te Velde ER, Broekmans FJ. :Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. Journal of Clinical Endocrinology and Metabolism. 2006;91: 4057 – 4063. DOI:

Sower MR, Eyvazzadeh, AD, McConnell D, Yosef M, Jannausch ML, Zhang D.:Anti-Mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. Journal of Clinical Endocrinology and Metabolism. 2008; 93(9): 3478 – 3483. DOI:

Daniel WW. : Biostatistics: A Foundation for Analysis in the Health Sciences. 7th edition. New York: John Wiley and Sons, 1999

Bentzen I, Frii-Hansen: Ovarian Reserve Parameters and Comparison between users and non-users of hormonal contraception. Reproductive Biomedicine2012; 25:612-619. DOI:

Owolabi AT, Fasubaa OB, Ogunniyi SO.: Semen quality of infertile male couples in Ile –Ife, Nigeria, Nigerian Journal of Clinical Prac, 2013; 16: 37-40. DOI:

de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. AntiMullerian hormone serum levels: a putative marker for ovarian aging.Fertility and Sterility,2020; 77: 357-62. DOI:

Chang MY, Chiang CH, Hsieh TT, Soong YK, Hsu KH.: Use of the antral follicle count to predict the outcome of assisted reproductive technologies. Fertility and Sterility1998; 69: 505-10. DOI:

Klein NA, Battaglia DE, Miller PB, Branigan EF, Giudice LC, Soules MR. Ovarian follicular development and the follicular fluid hormones and growth factors in normal women of advanced reproductive age. J Clin Endocrinol Metab 1996;81:1946–51. DOI:

McGee EA, Hsueh AJ.: Initial and cyclic recruitment of ovarian follicles. Endocrine Review2000; 21: 200-14. DOI:

Jong EL, Sang HY, Hye OK, Eug GM: Correlation between serum luteinizing hormone to follicle-stimulating hormone ratio and anti-Mullerian hormone level in normo-ovulatory women, Journal of Korean Medical Science,2015; 30:296-300. DOI:

Sun W, Stegman BJ, Henne M, Catherino MH, Segars JH.: A new approach to ovarian reserve testing. Fertil Steril, 2008; 90: 196-202 DOI:

Antonia LM, Valentine G. : AMH: usefulness in clinical practice 2013; International Journal of Endocrinology(13) accessed July 18, 2019, . DOI:

Most read articles by the same author(s)